Inventage Lab introduces ‘IVL-GeneFluidic®’ LNP manufacturing 바카라사이트 벳위즈 at ASGCT – Aiming for global CDMO market

[by Lee, Young Sung] Inventage Lab, a drug delivery technology 바카라사이트 벳위즈 company, announced on May 14 that it will showcase its next-generation gene therapy manufacturing 바카라사이트 벳위즈, ‘IVL-GeneFluidic®,’ based on lipid nanoparticles (LNPs), along with its research and process automation equipment, ‘HandyGene,’ at the ‘28th American Society for Gene & Cell Therapy (ASGCT) 2025.’ The company plans to present these technologies through a single booth at the conference taking place in New Orleans, USA, from May 13 to 17 (local time).

The American Society for Gene & Cell Therapy (ASGCT) is the world’s leading academic conference in the field of gene and cell therapy, attracting over 10,000 pharmaceutical and biotechnology professionals from around the world. It serves as a key 바카라사이트 벳위즈 for appraising the latest technological trends and advancements in next-generation treatment development.

At the conference, Inventage Lab will showcase the fully technological capabilities of its integrated LNP manufacturing 바카라사이트 벳위즈, ‘IVL-GeneFluidic®’, for the first time in the world. The company aims to strengthen partnerships with international firms by promoting its vision of becoming a ‘Gene to GMP’ contract development and manufacturing organization (CDMO), supported by an automated system that seamlessly connects research to GMP production.

‘IVL-GeneFluidic®’ is a microfluidic-based automated 바카라사이트 벳위즈 designed for the efficient and reproducible manufacturing of mRNA and LNP formulations. This next-generation, CDMO-exclusive system simultaneously supports rapid experimental optimization, scalable production, and process validation. It is powered by the independently developed HandyGene equipment from Inventage Lab, which stands out as an integrated solution that seamlessly connects laboratory screening to large-scale GMP manufacturing in a single workflow, providing comprehensive support for the design, production, and quality control of LNP formulations.

Inventage Lab is at the forefront of several large-scale national R&D projects centered on LNP technology, positioning itself as a key player in the Korean 바카라사이트 벳위즈 therapy and mRNA vaccine industries.

Notably, 바카라사이트 벳위즈 Lab is currently participating in the 'Development of Advanced Vaccine Raw Materials Production Technology (Development of Vaccine Production Process Technology)' project led by the Ministry of Trade, Industry and Energy, as well as the 'Establishment of a Vaccine Decentralized Production System' initiative, part of the 'Korean ARPA-H' (Advanced Research Projects Agency for Health and Medical Affairs) project led by the Ministry of Health and Welfare and the Korea Health Industry Development Institute (KHIDI).

Recently, Inventage Lab was selected for the 'Development of Pandemic Response mRNA Vaccines' national project, led by the Korea Disease Control and Prevention Agency. As part of this initiative, the company is conducting non-clinical research on vaccines for responding to COVID-19 variants and emerging variant infectious diseases. Through this project, Inventage Lab is accelerating the localization of LNP manufacturing technology for next-바카라사이트 벳위즈ration mRNA vaccines and establishing a rapid response capability.

"At this year’s ASGCT, we will present our proprietary technology and GMP-compliant automation solutions to a global audience for the first time, solidifying our position in the gene therapy CDMO market," an Inventage Lab official stated. “HandyGene is a core component of a 바카라사이트 벳위즈 that extends beyond basic research equipment, supporting both clinical and commercial production. Meanwhile, the IVL-GeneFluidic® 바카라사이트 벳위즈 represents a next-generation manufacturing technology that has attracted interest from major global pharmaceutical companies, marking a potential turning point in the global CDMO paradigm.”

“This conference holds particular significance as it marks the first global showcase of the IVL-GeneFluidic® 바카라사이트 벳위즈, which has recently garnered significant market attention and generated high expectations following the promising results of our oral GLP-1 treatment,” the official further commented. “We will continue to refine our 바카라사이트 벳위즈 technologies to demonstrate our competitiveness in the global gene therapy development market.”